ACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.13 per share and revenue of $273.04 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $19.95 on Monday. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $26.56. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of 25.58 and a beta of 0.37. The firm’s fifty day moving average price is $18.20 and its 200 day moving average price is $16.73.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ACAD. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.